<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04279769</url>
  </required_header>
  <id_info>
    <org_study_id>CX-280-202</org_study_id>
    <nct_id>NCT04279769</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis</brief_title>
  <official_title>A Phase 1b Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calithera Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calithera Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b multiple ascending dose escalation study to evaluate the safety and&#xD;
      tolerability of arginase inhibitor CB-280 in subjects with cystic fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study CX-280-202 is a Phase 1b, randomized, double-blind, placebo-controlled, multiple&#xD;
      ascending dose escalation study of CB-280 in adult subjects with cystic fibrosis and chronic&#xD;
      infection with Pseudomonas aeruginosa. The study will evaluate the safety, pharmacokinetics,&#xD;
      pharmacodynamics, and biological activity of CB-280 in approximately 32 adult patients with&#xD;
      cystic fibrosis. There are four planned sequential dose escalation cohorts of 8 subjects&#xD;
      each, randomized 6:2 to receive CB-280 or matched placebo at doses of 50 mg, 100 mg, 200 mg,&#xD;
      or 400 mg administered twice daily for 14 days. Intermediate dose levels may be evaluated&#xD;
      based on emerging safety data at the planned dose levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety and tolerability of CB-280 in adult cystic fibrosis patients: incidence and severity of adverse event (AEs) assessed by Common Terminology Criteria for Adverse Events, version 5 (CTCAE v5.0)</measure>
    <time_frame>Start of treatment to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of plasma CB-280 measured by Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of plasma CB-280 measured by area under the plasma concentration versus time curve, from time 0 to the last observed non-zero concentration (AUC 0-t)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-280 twice daily at 50 mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-280 twice daily at 100 mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-280 twice daily at 200 mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-280 twice daily at 400 mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-280</intervention_name>
    <description>CB-280, oral capsule administered twice daily at the assigned dose level for 14 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo oral capsule administrated twice daily at the assigned dose level for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written Informed Consent in accordance with federal, local, and institutional&#xD;
             guidelines&#xD;
&#xD;
          2. Confirmed diagnosis of cystic fibrosis&#xD;
&#xD;
          3. Male or female subjects ≥ 18 years on the date of informed consent&#xD;
&#xD;
          4. Percent predicted FEV1 of 40-90% at screening per Global Lung Function Initiative&#xD;
             (GLI) equation&#xD;
&#xD;
          5. Clinically stable with no significant changes in health status within 28 days prior to&#xD;
             Day 1&#xD;
&#xD;
          6. Chronic lung infection with P. aeruginosa defined as at least one positive culture in&#xD;
             the last two years and more than 50% of cultures positive since then&#xD;
&#xD;
          7. Stable cystic fibrosis medication regimen for at least 28 days inclusive of CFTR&#xD;
             modulators prior to Day 1&#xD;
&#xD;
          8. Hemoglobin &gt; 10 g/dL at screening&#xD;
&#xD;
          9. Glomerular filtration rate &gt; 50 mL/min/1.73 m2 at screening&#xD;
&#xD;
         10. Normal liver function at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of any comorbidity that, in the opinion of the Investigator, might pose an&#xD;
             additional risk in administering study drug to the subject or confound the results of&#xD;
             the study&#xD;
&#xD;
          2. Lung infection with organisms associated with a more rapid decline in pulmonary status&#xD;
             (including, but not limited to, Burkholderia cenocepacia, Burkholderia dolosa, and&#xD;
             Mycobacterium abscessus)&#xD;
&#xD;
          3. Unable to receive study medication per os (PO)&#xD;
&#xD;
          4. Females who are pregnant, have a positive pregnancy test at screening, or are nursing&#xD;
             (lactating)&#xD;
&#xD;
        Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emil T Kuriakose, MD</last_name>
    <role>Study Director</role>
    <affiliation>Calithera Bioscience</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Administrator</last_name>
    <phone>650-870-1000</phone>
    <email>clinicaltrials@calithera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Hicks</last_name>
      <phone>501-686-5525</phone>
    </contact>
    <investigator>
      <last_name>Larry Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candice Evans</last_name>
      <phone>714-822-1606</phone>
    </contact>
    <investigator>
      <last_name>Jimmy Johannes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noni Granham</last_name>
      <phone>352-294-5195</phone>
    </contact>
    <investigator>
      <last_name>Cesar Trillo-Alvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cystic Fibrosis Institute</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Cruz</last_name>
      <phone>847-998-3434</phone>
    </contact>
    <investigator>
      <last_name>Steven Boas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Hempfling</last_name>
      <phone>317-278-0079</phone>
    </contact>
    <investigator>
      <last_name>Cynthia Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan White</last_name>
      <phone>913-588-6045</phone>
    </contact>
    <investigator>
      <last_name>Joel Mermis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azar Nouraky</last_name>
      <phone>410-502-0947</phone>
    </contact>
    <investigator>
      <last_name>Noah Lechtzin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital, Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Giancola</last_name>
      <phone>617-355-6665</phone>
    </contact>
    <investigator>
      <last_name>Gregory Sawicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Harmala</last_name>
      <phone>406-435-5137</phone>
    </contact>
    <contact_backup>
      <phone>406-435-2500</phone>
    </contact_backup>
    <investigator>
      <last_name>Jerimiah Lysinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Medical College at Westchester Medical Center</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Ramirez</last_name>
      <phone>914-493-7585</phone>
    </contact>
    <investigator>
      <last_name>Allen Dozor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Marsico Clinical Research Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Nesbitt</last_name>
      <phone>984-974-2960</phone>
    </contact>
    <investigator>
      <last_name>Scott H Donaldson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Schaefer</last_name>
      <phone>216-844-3267</phone>
    </contact>
    <investigator>
      <last_name>Kimberly McBennett, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hershey Medical Center Pennsylvania State University</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Diane Kitch</last_name>
      <phone>717-531-8521</phone>
    </contact>
    <investigator>
      <last_name>Judie Howrylak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashly Warden</last_name>
      <phone>843-792-4349</phone>
    </contact>
    <investigator>
      <last_name>Patrick Flume, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Francis</last_name>
      <phone>801-587-8105</phone>
    </contact>
    <investigator>
      <last_name>Theodore G Liou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vermont Lung Center at the University of Vermont Medical Center</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <zip>05446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Sweet</last_name>
      <phone>802-847-2193</phone>
    </contact>
    <investigator>
      <last_name>Charlotte Teneback, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RyN Hayden</last_name>
      <phone>203-500-9655</phone>
    </contact>
    <investigator>
      <last_name>Nauman Chaudary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Griffin</last_name>
      <phone>416-864-6060</phone>
      <phone_ext>3936</phone_ext>
    </contact>
    <investigator>
      <last_name>Michael Parkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Pauls' Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alireza Mojibian</last_name>
      <phone>(604) 682-2344</phone>
    </contact>
    <investigator>
      <last_name>Bradley Quon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Pelissier, MD</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>61834</phone_ext>
    </contact>
    <investigator>
      <last_name>Larry Land, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arginase inhibitor</keyword>
  <keyword>CB-280</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

